Phospholipid membrane quercetin nanoparticles as well as preparation method and application thereof
Through the phospholipid membrane-coated quercetin nanoparticles technology, the problem of poor water solubility in atherosclerosis treatment is solved, and the efficient distribution and targeted treatment of quercetin in the body is achieved, which significantly inhibits atherosclerosis and demonstrate good biosecurity.
Patent Information
- Application Number
- CN202410923813.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-22
Smart Images

Figure CN118986926A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of drug modification and preparation, and in particular to phospholipid membrane quercetin nanoparticles and a preparation method and application thereof. Background Art
[0002] Atherosclerosis (AS) is a chronic inflammatory vascular disease and the main pathological basis of cardiovascular disease (CVD). Lipids, fibers and calcifications in blood vessels accumulate in arteries, causing vascular inflammation and tissue proliferation, blocking blood vessels, restricting blood flow to various organs, and causing various cardiovascular complications. Therefore, drug intervention treatment targeting the pathogenesis of AS has important theoretical value and clinical application prospects for the prevention and treatment of cardiovascular and cerebrovascular diseases and people's life and health. Quercetin (Que) is a flavonoid compound derived from plants. As an anti-apoptotic and antioxidant agent, it can protect against damage to multiple organs. It has anti-cancer, anti-inflammatory, antibacterial, antiviral, hypoglycemic, hypotensive, immune function regulating and cardiovascular protection effects. It can be seen that quercetin is a drug that can effectively intervene and treat the pathogenesis of AS. However, due to the low water solubility of Que, it is difficult to achieve an effective blood drug concentration by oral administration of Que, resulting in a low drug concentration in the lesion site. Que is difficult to play an effective role in the clinical treatment of AS, and Que needs to be further processed to effectively exert its efficacy. Summary of the invention
[0003] The present invention provides a phospholipid membrane quercetin nanoparticle and a preparation method and application thereof, so as to solve the technical problem that oral Que is difficult to play an effective role in the clinical treatment of AS due to the low water solubility of Que.
[0004] The technical solution adopted by the present invention is as follows:
[0005] A phospholipid membrane quercetin nanoparticle comprises a quercetin modified inner core and a phospholipid membrane on the outer layer of the inner core, wherein the molecular formula of the quercetin modified inner core is as shown in Formula 1:
[0006]
[0007] Preferably, the particle size of the phospholipid membrane quercetin nanoparticles is 134.3±6.72 nm, the polydispersity index PDI is 0.217, and the zeta potential is -14.4±0.97 mV.
[0008] The method for preparing the phospholipid membrane quercetin nanoparticles comprises the following steps:
[0009] (1) Using DMSO as solvent, the quercetin modified core material was fully dissolved to obtain Mod-Que solution for later use, and using ethanol as solvent, DSPE-PEG solution, DOPC solution, and cholesterol solution were prepared for later use;
[0010] (2) adding ethanol aqueous solution to a reaction vessel and preheating to 35-40° C., and then rapidly adding DSPE-PEG solution, DOPC solution, cholesterol solution, Mod-Que solution and distilled water under stirring;
[0011] (3) Introducing compressed air into the reaction system, and removing the compressed air after the reaction is completed, thereby obtaining a phospholipid membrane quercetin nanoparticle solution.
[0012] Furthermore, the concentrations of the solutions prepared in step (1) are: the concentration of the Mod-Que solution is 20 mg / mL, and the concentrations of the DSPE-PEG solution, the DOPC solution, and the cholesterol solution are all 5 mg / mL.
[0013] Furthermore, in step (2), the volume ratio of DSPE-PEG solution, DOPC solution, cholesterol solution, Mod-Que solution and distilled water is 1:20:5.2:2.4:80.
[0014] Furthermore, the volume ratio of the ethanol aqueous solution to distilled water is 1:1, and the ethanol aqueous solution is an ethanol aqueous solution in which ethanol accounts for 30% by volume.
[0015] The phospholipid membrane quercetin nanoparticles are used in the preparation of atherosclerosis intervention and treatment drugs.
[0016] In summary, compared with the prior art, the present invention has the following advantages and beneficial effects:
[0017] 1. The phospholipid membrane quercetin nanoparticles PM-Que prepared by the method of the present invention have uniform particle size, good dispersibility, and stable properties in water. TEM further proves that PM-Que is a spherical nanoparticle with uniform appearance. In addition, the PM-Que prepared by the present invention has good solubility and a drug loading of 22.73%, which means that in the preparation process, if 1 mg of Que is added, 227.3 μg can be loaded, which greatly improves the solubility of quercetin in water and solves the technical problem of the prior art that the efficacy of Que is affected by poor water solubility;
[0018] 2. It is not difficult to see from in vitro experiments that PM-Que prepared by the present invention has good cell safety, can bind to LDL in the blood, circulate in the body through LDL, has the ability to enter cells through the LDL pathway, and has the ability to protect cells from ferroptosis, thereby inhibiting cell ferroptosis and thus playing an anti-AS function;
[0019] 3. It is not difficult to see from the in vivo experiments on mice that PM-Que prepared by the present invention can escape the clearance of the immune system and stay in the blood for a long time, thereby maintaining the efficacy for a long time; when PM-Que circulates in the body through the blood, a very small amount is taken up by normal blood vessels, and most of it can be accurately targeted to the AS plaque site and engulfed by inflammatory cells at the plaque site, indicating that PM-Que has a high drug utilization rate and low toxic side effects; PM-Que has a good therapeutic effect on AS and inhibits the development of AS. It reduces the lipid and collagen deposition of plaques, maintains endothelial integrity, and reduces the risk of plaque fragmentation; PM-Que can reduce the expression of iron death markers at the plaque site, indicating that PM-Que can inhibit the development of AS by inhibiting the iron death of endothelial cells and macrophages at the plaque site; PM-Que has good biosafety, has no obvious toxic side effects on organisms, and is suitable for long-term administration and treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 Schematic diagram of the phospholipid membrane coating process of the phospholipid membrane quercetin nanoparticles of the present invention;
[0021] Figure 2 This is the particle size distribution diagram of PM-Que prepared in Example 1 in aqueous solution;
[0022] Figure 3 This is a transmission electron microscopy image of PM-Que nanoparticles prepared in Example 1, with a scale of 100 nm.
[0023] Figure 4 This is a diagram showing the surface potential of PM-Que prepared in Example 1 in aqueous solution;
[0024] Figure 5 This is a graph showing the change in particle size of PM-Que prepared in Example 1 in aqueous solution;
[0025] Figure 6 It is a bar graph of endothelial cell viability after being treated with different concentrations of blank lipids, Mod-Que and PM-Que;
[0026] Figure 7 It is a bar graph of cell viability of endothelial cells treated with different concentrations of PM-Que;
[0027] Figure 8 It is a bar graph of cell viability of macrophages treated with different concentrations of PM-Que;
[0028] Fig. 9Figures showing the ability of PM-Que to enter cells, including (a) a flow cytometry fluorescence intensity analysis of endothelial cells engulfing PM-Que, and (b) a flow cytometry quantitative analysis of endothelial cells engulfing PM-Que;
[0029] Fig.10 Figures showing the ability of endothelial cells to phagocytose PM-Que, including (a) flow fluorescence intensity analysis of endothelial cells phagocytosing PM-Que from mouse blood after LDLR treatment, (b) flow fluorescence quantitative analysis of endothelial cells phagocytizing PM-Que after LDLR treatment, (c) flow fluorescence intensity analysis of endothelial cells phagocytizing PM-Que containing different LDL concentrations, (d) flow quantitative intensity analysis of endothelial cells phagocytizing PM-Que containing different LDL concentrations;
[0030] Fig.11 Figures showing the study of the ability of macrophages to phagocytose PM-Que, including: (a) flow fluorescence intensity analysis of LDLR-treated macrophages phagocytizing PM-Que from mouse blood; (b) flow fluorescence quantitative analysis of LDLR-treated macrophages phagocytizing PM-Que; (c) flow fluorescence intensity analysis of macrophages phagocytizing PM-Que containing different LDL concentrations; (d) flow quantitative intensity analysis of macrophages phagocytizing PM-Que containing different LDL concentrations;
[0031] Fig.12 This is a comparison of the ability of macrophages and endothelial cells to phagocytize PM-Que;
[0032] Fig.13 The cell viability of endothelial cells and macrophages after Erastin treatment, including (a) cell viability of endothelial cells after Erastin treatment, (b) cell viability of macrophages after Erastin treatment;
[0033] Fig.14 Figures showing the ability of PM-Que to protect endothelial cells from ferroptosis, including: (a) cell viability of endothelial cells that have undergone ferroptosis after being treated with Ferrostatin-1, (b) cell viability of endothelial cells that have undergone ferroptosis after being treated with PM-Que;
[0034] Fig.15 Figures showing the ability of PM-Que to protect macrophages from ferroptosis, including: (a) a graph showing cell viability of ferroptotic macrophages treated with Ferrostatin-1, and (b) a graph showing cell viability of ferroptotic macrophages treated with PM-Que;
[0035] Fig.16Cell viability diagrams of macrophages and endothelial cells treated with PM-Que and the ferroptosis inhibitor Ferrostatin-1, including (a) cell viability diagram of endothelial cells that have undergone ferroptosis treated with 1 μM Ferrostatin-1 and PM-Que, (b) cell viability diagram of macrophages that have undergone ferroptosis treated with 5 μM Ferrostatin-1 and PM-Que;
[0036] Fig.17 It is a line graph of the blood fluorescence intensity of PM-Que and Mod-Que after they circulate in mice for different periods of time;
[0037] Fig.18 Figures showing the study of PM-Que targeting AS in vivo, including (a) fluorescence intensity of blood vessels in mice 24 hours after injection of PM-Que and Mod-Que, (b) fluorescence quantitative statistics of blood vessels in mice 24 hours after injection of PM-Que and Mod-Que;
[0038] Fig.19 The fluorescence intensity diagram of the main organs of mice injected with PM-Que and Mod-Que 24 hours later, the scale bar is 2 cm;
[0039] Fig. 20 This is the co-localization map of PM-Que with endothelial cells and macrophages in the tubular plaque, the scale bar is 50 μm;
[0040] Fig.21 This is the co-localization image of PM-Que with endothelial cells and macrophages in normal blood vessels, the scale bar is 50 μm;
[0041] Fig. 22 The results of Oil Red O staining of aorta of mice in different treatment groups;
[0042] Fig.23 The Oil Red O staining images of the aortic arch root sections of mice in each group after different treatments. The upper image of each group is the original image with a scale bar of 500 μm, and the lower image of each group is the enlarged image with a scale bar of 100 μm;
[0043] Fig.24 The necrotic nuclear staining images of the aortic arch root sections of mice in each group after different treatments. The upper image of each group is the original image with a scale bar of 500 μm, and the lower image of each group is the enlarged image with a scale bar of 100 μm;
[0044] Fig.25 The MMP-9 immunohistochemistry images of the aortic arch root sections of mice in each group after different treatments, the upper image of each group is the original image with a scale bar of 500 μm, and the lower image of each group is the enlarged image with a scale bar of 100 μm;
[0045] Fig.26CD31 immunohistochemistry images of aortic arch root sections of mice after different treatments. The upper image of each group is the original image with a scale bar of 500 μm, and the lower image of each group is the enlarged image with a scale bar of 100 μm;
[0046] Fig. 27 The CD68 immunohistochemistry images of the aortic arch root sections of mice after different treatments, the upper image of each group is the original image with a scale bar of 500 μm, and the lower image of each group is the enlarged image with a scale bar of 100 μm;
[0047] Fig.28 The α-SMA immunohistochemistry images of the aortic arch root sections of mice after different treatments, the upper image of each group is the original image with a scale bar of 500 μm, and the lower image of each group is the enlarged image with a scale bar of 100 μm;
[0048] Fig.29 HE staining images of the main organs of mice in each group after different treatments, the scale bar is 100 μm;
[0049] Fig.30 This is a line graph of the body weight of mice in each group after different treatments. DETAILED DESCRIPTION
[0050] In order to make the purpose, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with various embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention, that is, the embodiments described are only part of the embodiments of the present invention, rather than all of the embodiments.
[0051] The word "embodiment" used here as an "exemplary" does not necessarily mean that any embodiment described is superior to or better than other embodiments. Unless otherwise specified, the performance index tests in the embodiments of this method adopt conventional test methods in the art. The terms described in the present invention are only for describing specific implementation methods and are not intended to limit the content disclosed in the present invention.
[0052] Unless otherwise specified, the technical and scientific terms used herein have the same meanings as commonly understood by ordinary technicians in the technical field to which the invention belongs; other raw materials, reagents, experimental methods and technical means not specifically specified in the present invention refer to the raw materials and reagents commonly used by ordinary technicians in the field, as well as the commonly used experimental methods and technical means.
[0053] Example 1
[0054] This embodiment discloses a preparation process of quercetin nanoparticles using phospholipid membranes: first, quercetin is chemically modified, and then the phospholipid membrane is coated on the chemically modified quercetin modified core to obtain PM-Que.
[0055] 1. Chemical modification of quercetin to obtain Mod-Que
[0056] This step is completed by Chongqing Southwest Pharmaceutical Co., Ltd., and its reaction process is shown in Formula 2:
[0057]
[0058] 2. Coat Mod-Que with a phospholipid membrane to obtain PM-Que
[0059] like Figure 1 As shown in the figure, the preparation process of phospholipid membrane quercetin nanoparticles is shown. The process of coating the phospholipid membrane is as follows:
[0060] (1) Preparation of reaction solution: 30 mL of anhydrous ethanol was heated to 65°C and then dispensed into three 20 mL glass bottles, 10 mL in each bottle; 50 mg of DSPE-PEG2000, DOPC and cholesterol were weighed and added into 10 mL of anhydrous ethanol at 65°C respectively, and after being fully dissolved, 5 mg / mL DSPE-PEG2000 solution, DOPC solution and cholesterol solution were prepared respectively; 20 mg of Mod-Que prepared by Chongqing Southwest Pharmaceutical was weighed and added into 10 mL of DMSO solution, and fully dissolved to obtain a 20 mg / mL Mod-Que solution; 3 mL of anhydrous ethanol was taken and 7 mL of distilled water were taken and fully mixed to obtain a 30% ethanol aqueous solution.
[0061] (2) Feeding: Set the temperature of the thermostatic stirrer to 37°C and the speed to 1250 rpm. After heating, place a 20 mL glass bottle with a magnetic rotor in the thermostatic stirrer. After the rotor is stably located in the center of the glass bottle, add 2 mL of 30% ethanol aqueous solution to the glass bottle and preheat for 3 min. Then quickly add 25 μL DSPE-PEG2000, 500 μL DOPC, 130 μL cholesterol, 60 μL Mod-Que, and 2 mL distilled water to the preheated ethanol aqueous solution and stir thoroughly.
[0062] (3) Pressurized reaction: Introduce compressed air into the glass bottle to accelerate the volatilization of the organic reagent. After 5 minutes of reaction, observe the color of the remaining solution in the glass bottle. When the remaining solution is milky white, measure the volume of the remaining solution. When the remaining solution is 1.4 mL, remove the compressed air and turn off the constant temperature magnetic stirrer to collect the remaining solution. The remaining solution at this time is estimated to be 0.8 mg / mL PM-Que solution. The obtained PM-Que solution is stored at 4°C.
[0063] 3. Characterize the morphology and potential of PM-Que in the obtained PM-Que solution
[0064] The hydrated particle size and potential of PM-Que were measured at room temperature using a Malvern laser particle size potentiometer, and each sample was measured three times. Take 1mL of the prepared PM-Que solution, dilute it five times with pure water and mix it thoroughly, and measure the hydrated particle size and potential. The specific morphological characteristics of the nanoparticles were measured by transmission electron microscopy (TEM). Take 20μL of the prepared PM-Que, drop it on a 200-mesh copper grid, let it air dry naturally at room temperature, continue to drop 20uL of PM-Que on the copper grid, and after air drying again, add 20μL of 5% phosphotungstic acid solution to the copper grid, leave it at room temperature for 5min, absorb the residual phosphotungstic acid solution, and continue to air dry for 1h. Place the prepared copper grid under the TEM selection area for observation to observe the specific morphological characteristics of PM-Que.
[0065] In this example, the hydrated particle size of PM-Que was measured by dynamic light scattering (DLS). Figure 2 As shown, the average hydrated particle size of PM-Que is 134.3±6.72nm, and its polydispersity index (PDI) is 0.217. PDI is an indicator to measure the dispersion coefficient of polymers. In the particle size measurement results, it represents the uniformity of particle size distribution. The smaller the PDI, the more uniform the particle size. Figure 2 This shows that the PM-Que prepared in this study has a small particle size and is evenly distributed in the solution. In order to further understand the morphological characteristics of PM-Que, this study used a transmission electron microscope to observe it in detail. The results are as follows Figure 3 As shown, PM-Que synthesized by nanoprecipitation method has a uniform spherical appearance with a particle size of about 100 nm. It is normal that the TEM particle size is smaller than that of the DLS because the TEM sample has been dehydrated.
[0066] like Figure 4 As shown in the figure, it is the surface potential of PM-Que in aqueous solution. Zeta potential is a measure of the interaction between particles. The higher the absolute value of the Zeta potential of the nanoparticles, the more stable the system. The potential of PM-Que is -14.4±0.97mV, indicating that PM-Que has good stability in the solution. Figure 5 As shown, the particle size change of PM-Que within 72 hours at room temperature. It can be seen from the figure that the particle size of PM-Que in aqueous solution has no obvious change, indicating that long-term placement of PM-Que will not affect its particle size, indicating that PM-Que has good stability in aqueous solution.
[0067] 4. Detect the drug loading and encapsulation efficiency of PM-Que
[0068] Take 12 μL of 20 mg / mL Mod-Que solution, add 288 μL of DMSO solution, and mix thoroughly to obtain a Mod-Que dilution solution; add 100 μL of Mod-Que dilution solution, the obtained PM-Que solution, DMSO, and distilled water to a 96-well plate, repeat three times, and measure the absorbance at 370 nm with a fluorescence microplate reader.
[0069] PM-Que encapsulation rate (%) = (Que in PM-Que / Que added during preparation) × 100%
[0070] Drug loading of PM-Que (%) = (Que in PM-Que / mass of PM-Que) × 100%
[0071] As shown in Table 1, the encapsulation efficiency and drug loading of PM-Que prepared in this example are as follows:
[0072] Table 1 Encapsulation efficiency and drug loading of PM-Que
[0073] Sample Encapsulation rate (%) Drug loading (%) PM-Que 84.77±0.21 22.73±0.03
[0074] The solubility of ordinary quercetin in water is only 0.01 mg / mL. The drug loading of PM-Que prepared in this embodiment is 22.73%, which means that if 1 mg of Que is added during the preparation process, 227.3 μg can be loaded, which greatly improves the solubility of quercetin in water; the encapsulation rate also reaches 84.77%, indicating that the PM-Que prepared in this embodiment has a good coating effect, further ensuring the stability of PM-Que in aqueous solution.
[0075] Example 2
[0076] This example conducts in vitro evaluation on PM-Que obtained in Example 1, mainly including the following operations:
[0077] 1. Cytotoxicity experiment of PM-Que
[0078] Endothelial cell CCK-8 experiment: When the endothelial cells in the culture dish grow to about 80%, discard the old culture medium, add PBS to gently wash and remove the residual culture medium, and repeat the operation 3 times. Add 2mL of trypsin to the culture dish and gently shake the culture dish to cover all cells with trypsin, and then wait for digestion to be completed. Observe under a microscope. When most of the cells change from irregular cobblestones to round shapes, it means that digestion is complete and trypsin can be discarded. If there is no such phenomenon, let the cells continue to digest until digestion is complete. Add 8mL of complete culture medium and gently blow down the cells and mix them, and inoculate them into two 96-well plates, 100μL per well. Blank lipids, Mod-Que and PM-Que were added to one plate, and the concentrations were set to 0.5, 1, and 2μM. In the other plate, the concentration gradient of PM-Que was set to 0, 1, 2, 3, 4, and 5μM, with 3 parallels for each concentration. After the 96-well plate was incubated in a 37°C, 5% CO2 constant temperature incubator for 12 hours, 10 μL of drug solution was added to each well for co-incubation. After 12 hours, 10 μL of CCK-8 reagent was added to each well (the operation should be protected from light), and the plate was incubated in a 37°C, 5% CO2 constant temperature incubator for 2.5 hours in a dark place, and the absorbance at 450 nm was detected using an ELISA reader.
[0079] Macrophage CCK-8 experiment: When the macrophages grow to about 80% in the culture flask, discard the old culture medium, add PBS to gently rinse to remove the residual culture medium, and repeat PBS rinsing 3 times. Add 8mL of complete culture medium, gently blow down the cells and mix them, and inoculate them into a 96-well plate, 100μL per well. Set the concentration gradient of PM-Que drug to 0, 5, 10, 15, 20, 25μM, with 3 parallels for each concentration. After the 96-well plate is cultured in a 37°C, 5% CO2 constant temperature incubator for 12h, add 10μL of drug solution to each well for co-incubation. After 12h, add 10μL CCK8 reagent to each well (operation needs to be protected from light), incubate in a 37°C, 5% CO2 constant temperature incubator for 2h in the dark, and then use an enzyme reader to detect the absorbance at 450nm.
[0080] The CCK-8 kit can detect cell toxicity quickly and sensitively. The WST-8 in the CCK-8 reagent can react with the dehydrogenase in the cell to generate a water-soluble orange-yellow formazan product. The color depth is related to the number of cells. The darker the color, the more living cells there are. In order to detect the concentration of PM-Que when it is toxic to endothelial cells and macrophages, this example inoculated endothelial cells and macrophages into a 96-well plate and incubated PM-Que with the cells for 12 hours. Figure 6As shown in the figure, Mod-Que and blank lipids have low toxicity to cells, while PM-Que has high toxicity to cells. As its concentration increases, it gradually produces obvious toxicity to cells. In order to specifically detect the concentration at which PM-Que produces toxicity to endothelial cells and macrophages, this study seeded endothelial cells and macrophages into 96-well plates, incubated PM-Que with cells for 12 hours, and then used CCK-8 kit to detect cell viability. The results are shown in the figure. Figure 7 As shown in the figure, with the increase of PM-Que concentration, the activity of endothelial cells gradually decreased. When 2 μM of the drug was added, the activity of endothelial cells had dropped to about 80%, indicating that it may be easier to enter the cells. It may be that the modified quercetin is easy to bind to phospholipids. The nano-size of the modified quercetin enhances its ability to enter cells and strengthens its biological function at the cellular level. Figure 8 As shown in the figure, with the increase of PM-Que concentration, the activity of macrophages gradually decreased. When the PM-Que concentration reached 15 μM, the cell survival rate was still higher than 80%. Figure 7 / 8, PM-Que is less toxic to macrophages, possibly because endothelial cells are more sensitive to PM-Que.
[0081] 2. PM-Que's ability to enter cells
[0082] (1) Study on the time dependence of cell phagocytosis of PM-Que
[0083] Preparation of PM-Que-DID: DID was added dropwise to PM-Que in a light-proof condition, mixed thoroughly and allowed to stand at room temperature for 3 h.
[0084] Preparation of PM-Que-LDL-DID in vitro: DID and LDL were added dropwise to PM-Que under light-protected conditions, mixed thoroughly, and allowed to stand at room temperature for 3 h.
[0085] After the endothelial cells grew to 70-80% in a six-well plate, the cells were starved for 6 hours. After starvation, a certain amount of PM-Que-LDL-DID was added to each well under light-proof conditions. The cells were incubated with PM-Que-LDL-DID for 1, 2, 4, and 8 hours, and each time gradient was repeated three times. After incubation, the culture medium was removed, the cells were gently washed 3 times with PBS, and trypsin was added to digest the cells. After digestion, the cells were gently blown off with PBS. The blown endothelial cells were collected in a 1.5 mL centrifuge tube, which was placed in a sealed light-proof ice box and then placed on a flow cytometer.
[0086] The ability of cells to phagocytize nanoparticles is affected by time. This example explores the ability of cells to phagocytize PM-Que at different times. Fig. 9As shown, the amount of PM-Que taken up by cells increases significantly with time, and the graph is close to a linear function. The cells have strong fluorescence at 8 hours. In order to compare the difference in the ability of endothelial cells and macrophages to phagocytize PM-Que, 8 hours is used in this example.
[0087] (2) Study on the ability of endothelial cells to phagocytose PM-Que in vitro
[0088] After the endothelial cells grew to 70-80% in the six-well plate, the cells were starved for 6 hours. During the starvation period, 150 μg of PM-Que-DID was injected into the tail vein of C57BL / 6 mice. After 3 hours, the mouse plasma was taken out and added to the six-well plate. LDLR antibodies were added to the wells containing mouse plasma, so that the final concentrations of LDLR antibodies were 0, 1, and 5 μg / mL, respectively. Each gradient was repeated three times. After 8 hours, the culture medium was removed, the cells were gently washed with PBS 3 times, and trypsin was added to digest the cells. After digestion, the cells were gently blown off with PBS. The blown endothelial cells were collected in a 1.5 mL centrifuge tube, which was placed in a closed light-proof ice box and then flow cytometry was performed.
[0089] After the endothelial cells grew to 70-80% in a six-well plate, the cells were starved for 6 hours. During the starvation period, PM-Que-LDL-DID was diluted to 0, 4, and 8 μg / μL (calculated as LDL) with 1640 culture medium, and then PM-Que-LDL-DID and LDLR were added to six plates together, and each concentration was repeated three times. After 8 hours, the culture medium was removed, the cells were gently washed 3 times with PBS, and trypsin was added to digest the cells. After digestion, the cells were gently blown off with PBS. The blown endothelial cells were collected in a 1.5 mL centrifuge tube, which was placed in a sealed light-proof ice box and then placed on a flow cytometer.
[0090] like Fig.10As shown in the figure, the ability of endothelial cells to phagocytize PM-Que injected into mice is affected by LDLR antibodies, and the ability of endothelial cells treated with different LDLR antibodies to phagocytize PM-Que is significantly different. The results show that after PM-Que is injected into the blood of mice, it will bind to LDL in the blood and enter the cells through the LDLR pathway. The phagocytic ability of endothelial cells that have not been treated with LDLR antibodies is the strongest. As the concentration of LDLR antibodies increases, the ability of endothelial cells to phagocytize PM-Que gradually weakens. The concentration of LDL will also affect the uptake of PM-Que by endothelial cells. By combining different concentrations of LDL with PM-Que, we found that the concentration of LDL will also affect the phagocytic ability of endothelial cells to phagocytize PM-Que. The more LDL that binds to PM-Que, the more PM-Que the endothelium phagocytizes. As the concentration of LDL increases, the ability of endothelial cells to uptake PM-Que is significantly enhanced. The above results show that PM-Que will bind to LDL in the blood, the entry of PM-Que into cells will be affected by the concentration of LDL, and the LDLR-mediated endocytosis pathway is the main pathway for endothelial cells to uptake PM-Que in the blood.
[0091] (3) Study on the ability of macrophages to phagocytize PM-Que in vitro
[0092] After the macrophages grew to 70-80% in the six-well plate, the cells were starved for 6 hours. During the starvation period, 150 μg of PM-Que-DID was injected into the tail vein of C57BL / 6 mice. After 3 hours, the mouse plasma was taken out and added to the six-well plate. LDLR antibodies were added to the wells containing mouse plasma, so that the final concentrations of LDLR antibodies were 0, 1, and 5 μg / mL, respectively. Each gradient was repeated three times. After 8 hours, the culture medium was removed, the cells were gently washed 3 times with PBS, and the cells were gently blown off with PBS. The blown macrophages were collected in a 1.5 mL centrifuge tube, which was placed in a closed light-proof ice box and then flow cytometry was performed.
[0093] After the macrophages grew to 70-80% in a six-well plate, the cells were starved for 6 hours. During the starvation period, PM-Que-LDL-DID was diluted to 0, 4, and 8 μg / μL (calculated as LDL) with DMEM medium, and then PM-Que-LDL-DID and LDLR were added to six plates together, with each concentration repeated three times. After 8 hours, the culture medium was removed, the cells were gently washed 3 times with PBS, and the cells were gently blown off with PBS. The blown macrophages were collected in a 1.5 mL centrifuge tube, which was placed in a sealed light-proof ice box and then flow cytometry was performed.
[0094] like Fig.11As shown in the figure, the ability of macrophages to phagocytize PM-Que injected into mice in vitro is affected by LDLR antibodies, and the ability of macrophages treated with different LDLR antibodies to phagocytize PM-Que is significantly different. The results show that after PM-Que is injected into the blood of mice, it will bind to LDL in the blood and enter the cells through the LDLR pathway. The phagocytic ability of macrophages that have not been treated with LDLR antibodies is significantly the strongest. As the concentration of LDLR antibodies increases, the phagocytic ability of macrophages to PM-Que gradually weakens. Similar to the results of endothelial cell experiments, LDL concentration will also affect the uptake of PM-Que by macrophages. After combining PM-Que with LDL of different concentrations, we found that LDL concentration affects the phagocytosis of PM-Que by macrophages. The more LDL that binds to PM-Que, the more PM-Que macrophages phagocytize. As the concentration of LDL increases, the ability of macrophages to uptake PM-Que is significantly enhanced. The above results indicate that PM-Que will bind to LDL in the blood, the entry of PM-Que into cells will be affected by the LDL concentration, and the LDLR-mediated endocytosis pathway is also the main pathway for macrophages to take up PM-Que in the blood.
[0095] like Fig.12 As shown, this example also compares the ability of endothelial cells and macrophages to phagocytize PM-Que under the same conditions. Under the same conditions, the ability of macrophages to phagocytize PM-Que is significantly stronger than that of endothelial cells, which may suggest that macrophages at the plaque can take up more PM-Que, which may be due to the characteristics of macrophages as immune cells. In addition, the strong phagocytic effect of macrophages on PM-Que suggests that only a small part of PM-Que in the body is phagocytosed by endothelial cells. Combined with the cytotoxicity experiment, it shows that PM-Que in the body will not have a large toxicity to endothelial cells.
[0096] 3. Biological function experiments of PM-Que
[0097] (1) Methods for inducing endothelial cell ferroptosis
[0098] When the endothelial cells in the culture dish grow to about 80%, remove the culture medium, gently wash the cells with PBS 3 times, add trypsin to digest the cells, and after digestion, gently blow down the endothelial cells with complete culture medium and mix them. Adjust the cell concentration after mixing and inoculate it into a 96-well plate, 200μL per well. When the cells in the well plate grow to 80%, discard the old culture medium and add fresh culture medium containing Erastin. The concentrations of Erastin are 0, 1, 2.5, 5, and 10μM, respectively, and three parallels are performed for each concentration. After 24h, discard the culture medium and add 100μL of culture medium containing 10% CCK-8 reagent to each well. Keep it away from light during this period. After 2.5h, use an enzyme reader to detect the absorbance at 450nm.
[0099] Ferroptosis is a new type of programmed cell death. Recent studies have confirmed that ferroptosis is associated with a variety of cardiovascular diseases and may be a potential target for the treatment of cardiovascular diseases. Increased iron levels in the body can induce increased vascular permeability and endothelial activation and dysfunction. At the same time, iron accumulation in macrophages can accelerate lipid accumulation and promote the occurrence and development of atherosclerosis. Therefore, AS can be treated by inhibiting ferroptosis of endothelial cells and macrophages.
[0100] This example first detected whether endothelial cells and macrophages are ferroptosis-sensitive cells. This study used the classic ferroptosis inducer Erastin to detect whether endothelial cells and macrophages can undergo intracellular ferroptosis. The results are as follows: Fig.13 As shown. After 2.5 μM Erastin was co-incubated with endothelial cells for 24 hours, the viability of endothelial cells had changed significantly, while the viability of macrophages was significantly changed only after co-incubation with Erastin at a concentration of more than 10 μM. The above results indicate that endothelial cells are more susceptible to ferroptosis than macrophages.
[0101] (2) Study on the ability of PM-Que to protect endothelial cells from ferroptosis
[0102] When the endothelial cells in the culture dish grow to about 80%, remove the culture medium, gently wash the cells with PBS 3 times, add trypsin to digest the cells, and after digestion, gently blow down the endothelial cells with complete culture medium and mix them. Adjust the cell concentration after mixing and inoculate them into a 96-well plate, 200μL per well. When the cells in the well plate grow to 80%, discard the old culture medium and add fresh culture medium containing 2.5μM Erastin. After 24h, discard the old culture medium and add fresh culture medium containing 2μM Ferrostatin-1 and PM-Que respectively, and repeat each concentration three times. After 12h, discard the culture medium and add 100μL of culture medium containing 10% CCK-8 reagent to each well, and keep it away from light during this period. After 2.5h, use an enzyme reader to detect the absorbance at 450nm.
[0103] The functional state of VECs plays an important role in maintaining vascular homeostasis. Dysfunction of VECs can lead to pathological changes in the cardiovascular system, which can cause diseases such as arteriosclerosis and hypertension. Protecting VECs from damage is of great significance for the prevention and treatment of atherosclerosis. Quercetin's ability to resist peroxidative damage is related to inhibiting the formation of reactive oxygen species and directly removing the reactive oxygen species that have been formed, which may indicate that quercetin can inhibit ferroptosis through antioxidant pathways. Therefore, this study verified whether PM-Que has a protective effect on VECs based on the occurrence of ferroptosis in VECs. After determining that Erastin can promote endothelial cell ferroptosis, we treated endothelial cells undergoing ferroptosis with different concentrations of PM-Que, and detected endothelial cell viability using the CCK-8 method to explore whether PM-Que has a protective effect on endothelial cells. The results are as follows: Fig.14 As shown in the figure, the viability of endothelial cells after Erastin treatment was only about 70%. After 1μM ferroptosis inhibitor Ferrostatin-1 was used to treat ferroptotic endothelial cells for 12h, the viability of endothelial cells increased significantly. Similar results were obtained after 1μM PM-Que was used to treat ferroptotic endothelial cells for 12h. Ferropoptosis of endothelial cells in AS sites promotes the development of plaques. PM-Que has the ability to protect endothelial cells from ferroptosis, indicating that PM-Que may protect endothelial cells with ferroptosis and inhibit the development of AS, thereby achieving a therapeutic effect.
[0104] (3) Study on the ability of PM-Que to protect macrophages from ferroptosis
[0105] When the macrophages in the culture dish grow to about 80%, remove the culture medium, gently wash the cells with PBS 3 times, and then gently blow down the macrophages with complete culture medium and mix them. Adjust the cell concentration after mixing and inoculate it into a 96-well plate, 200μL per well. When the cells in the well plate grow to 80%, discard the old culture medium and add fresh culture medium containing Erastin. The concentrations of Erastin are 0, 1, 2.5, 5, and 10μM, respectively, and three parallels are used for each concentration. After 24h, discard the culture medium and add 100μL of culture medium containing 10% CCK-8 reagent to each well. Keep it away from light during this period. After 2.5h, use an enzyme reader to detect the absorbance at 450nm.
[0106] When the macrophages in the culture dish grow to about 80%, remove the culture medium, wash the cells gently with PBS three times, and then gently blow down the macrophages with complete culture medium and mix them. Adjust the cell concentration after mixing and inoculate them into a 96-well plate, 200μL per well. When the cells in the well plate grow to 80%, discard the old culture medium and add fresh culture medium containing 2.5μM Erastin. After 24h, discard the old culture medium and add fresh culture medium containing 2μM Ferrostatin-1 and PM-Que respectively, and repeat three times for each concentration. After 12h, discard the culture medium and add 100μL of culture medium containing 10% CCK-8 reagent to each well, and pay attention to avoid light during this period. After 2.5h, use an enzyme reader to detect the absorbance at 450nm.
[0107] Macrophages are the main proinflammatory cells in atherosclerosis. Pathological studies have found a large number of dead macrophages in vulnerable plaques, and there is increasing evidence that macrophage death triggers inflammatory responses, leading to plaque instability. Inhibiting macrophage death may help prevent the progression and destabilization of atherosclerotic plaques. Natural antioxidants represented by quercetin have been shown to be effective against atherosclerosis. Quercetin can slow the progression of atherosclerosis by reducing oxidative stress levels and inhibiting macrophage death. After determining that PM-Que has a protective effect on endothelial cells undergoing ferroptosis, this example further verified the protective effect of PM-Que on macrophages undergoing ferroptosis, and used the CCK-8 method to detect macrophage viability. The results are as follows. Fig.15 As shown in the figure, the viability of macrophages treated with Erastin is only about 60%. After 12 hours of treatment of ferroptotic macrophages with 5μM Ferrostatin-1, the cell viability increased significantly. 5μM PM-Que has a similar effect on macrophages. Iron overload in macrophages at the AS site promotes the development of plaques and prevents macrophage ferroptosis. It can delay the development of atherosclerosis to a certain extent. PM-Que has the ability to protect macrophages from ferroptosis, indicating that PM-Que may protect macrophages with ferroptosis and inhibit the development of AS, thereby achieving a therapeutic effect.
[0108] In addition, this example further compares the difference in cell activity after treatment with PM-Que and the ferroptosis inhibitor Ferrostatin-1. Fig.16 As shown in the figure, PM-Que and Ferrostatin-1 at the same concentration have the same protective effect on the activity of endothelial cells that have undergone ferroptosis, and there is no significant difference. PM-Que and Ferrostatin-1 also have the same protective effect on the activity of macrophages that have undergone ferroptosis, and there is no significant difference, indicating that PM-Que has a similar function of inhibiting ferroptosis as Ferrostatin-1.
[0109] Example 3
[0110] This example conducts an in vivo evaluation of the PM-Que obtained in Example 1 on mice, which mainly includes the following operations:
[0111] 1. PM-Que residence time experiment in mice
[0112] Six eight-week-old C57BL / 6 mice were randomly divided into two groups and injected with 200 μL of 80 mg / mL PM-Que or Mod-Que. 20 μL of blood was collected from the tail tips of the mice at 1 h, 6 h, 12 h, 24 h, and 48 h, and the absorbance at 370 nm was measured using a microplate reader after dilution with 1×EDTA.
[0113] In order to verify whether PM-Que can have a long circulation time in mice and escape the clearance of the immune system to a certain extent, this example injects the same dose of PM-Que and Mod-Que into C57BL / 6 mice through the tail vein, and collects tail tip blood of mice at different time periods, and uses an ELISA reader to detect the absorbance value of the drug in the blood. The results are as follows: Fig.17 As shown in the figure, the tail tip blood was taken immediately after injection. The fluorescence intensity of PM-Que and Mod-Que in the mouse blood was very low. It may be that the sampling interval was too short and the drug circulation did not start in time. The concentration of Mod-Que in the blood reached its peak after 3 hours, and dropped to a low value after 6 hours. The signal of Mod-Que was almost undetectable in the following time period. The concentration of PM-Que reached its peak 6 hours after injection, and then slowly decreased. The fluorescence signal of PM-Que could still be detected in the blood at 48 hours, indicating that PM-Que has a significantly longer retention time in the blood than Mod-Que, and escaped the clearance of the immune system to a certain extent, achieving a long-term circulation effect.
[0114] 2. Study on PM-Que targeting AS in mice
[0115] Purchased 6-week-old ApoE - / - Several mice were first subjected to adaptive feeding for one week and then given a high-fat diet for 2 months to establish an atherosclerosis model.
[0116] (1) The 9 ApoE - / -Mice were randomly divided into 3 groups, 3 mice in each group. One group was injected with 200 μL PBS solution as blank control, and the other two groups were injected with 200 μL PM-Que marker and Mod-Que marker respectively. After 24 hours, each group was anesthetized and killed, and the mice were perfused with PBS containing heparin. The blood vessels, heart, liver, spleen, lung and kidney of the mice were taken out, and the residual blood on the organs was washed away with PBS. Each organ was stored in 4% paraformaldehyde in the dark, and excited and imaged at a wavelength of 640 nm using a small animal imaging system.
[0117] Example 2 proves that PM-Que in the blood can bind to LDL and has the ability to enter cells similar to LDL, but it cannot directly prove that PM-Que targets the AS site. Therefore, in this example, PM-Que was injected into the tail vein of mice, and the mouse aorta was imaged 24 hours later. The results are shown in Figure 2. Fig.18 As shown, compared with the Control group, PM-Que and Mod-Que both had fluorescence signals in the aorta area, indicating that part of PM-Que and Mod-Que reached the AS site. Compared with the Mod-Que group, the fluorescence signals of PM-Que in different parts of the aorta were significantly stronger, and Mod-Que had only a small amount of fluorescence signals in the aortic arch. The statistical results of fluorescence intensity showed that the average fluorescence intensity of the PM-Que group in the AS plaque site was 1.4 times that of Mod-Que, and more PM-Que reached the AS site, indicating that PM-Que has a significant ability to target AS plaques compared with Mod-Que. In addition, this example further analyzed the distribution of PM-Que in different organs. The drug administration method adopted in this study was tail vein injection. Before reaching the AS plaque, the drug must first circulate through the blood. The nanodrugs in the blood will first be taken up by the liver in large quantities. The uptake of the organs can illustrate the ability of the nanodrugs to escape clearance from the immune system. The fluorescence distribution of PM-Que and Mod-Que in the main organs of mice is shown in the figure. Fig.19 As shown. The fluorescence signal of Mod-Que on the liver is significantly stronger than that of PM-Que, indicating that the ability of Mod-Que in the blood to escape the clearance of the organism is weak, a large amount of Mod-Que is cleared by the body, and the drug utilization rate is low. The fluorescence signal of PM-Que on the liver is weak, and most of PM-Que is preserved in the blood and continues to participate in the circulation, which improves the drug utilization rate to a certain extent, proving that PM-Que can escape the clearance of the immune system to a certain extent and has a longer circulation time in the body than Mod-Que.
[0118] (2) To further demonstrate the ability of PM-Que to target AS plaques, three ApoE - / -Mice were injected with 200 μL PM-Que-DiD marker each, and then killed after 24 hours. The aorta was removed and frozen sections of the aortic arch root were prepared. The prepared frozen sections were stored at -20°C for immunofluorescence analysis. Fig. 20 As shown in Figure 1, there are a lot of PM-Que fluorescence signals at the plaque positions, whether in Plaque 1 or Plaque 2. Fig.21 As shown in the figure, there is almost no fluorescence signal of PM-Que in normal blood vessels, indicating that after PM-Que enters the blood circulation, it can target the AS lesions without affecting the normal blood vessels. This proves that PM-Que not only has the ability to target AS lesions similar to cell membrane-nanoparticles, but also has higher drug utilization and lower biological toxicity. Further analysis of the co-localization of PM-Que and cells in plaques, combined with Fig. 20 From the above, it can be seen that the PM-Que fluorescence signal at the plaque has less co-localization with the endothelial cell fluorescence, but more co-localization with the macrophages, indicating that after PM-Que reaches the plaque, most of the drug is phagocytosed by macrophages, and a small amount is phagocytosed by endothelial cells. Previous in vitro cell experiments have also proved that under the same conditions, the ability of macrophages to phagocytize PM-Que is stronger than that of endothelial cells. This confirms the results of previous cell experiments, indicating that the drugs at the plaque are mainly taken up by macrophages, which verifies the previous fact that macrophages have a stronger phagocytic ability than endothelial cells PM-Que.
[0119] 3. PM-Que for ApoE - / - Evaluation of therapeutic efficacy in mice
[0120] In this study, ApoE - / - The mice were given the drug for 30 days to evaluate the therapeutic effect of PM-Que on AS. After the end of the drug administration, the aorta of the mice was taken for Oil Red O staining. Fig. 22 As shown, Control is the untreated control group, Que group is the ordinary quercetin treatment group, Mod-Que is the modified quercetin treatment group, and PM-Que is the phospholipid membrane-quercetin nanoparticle treatment effect group. The Control group has a large amount of lipid deposition, indicating that ApoE after modeling - / -The mice had severe AS lesions, and the therapeutic effect of the Que group was worse than that of the Mod-Que and PM-Que groups. This may be because quercetin is a hydrophobic drug and is quickly cleared by the body after injection, so the therapeutic effect is weak. After quercetin is modified (Mod-Que), it is easier to bind to the phospholipids on the cell membrane, so the Mod-Que group has a better therapeutic effect than the Que group. Mod-Que is wrapped with a layer of phospholipid membrane and prepared as phospholipid membrane-quercetin nanoparticles (PM-Que). Phospholipids are wrapped around Mod-Que to form a hydrophilic shell. Previous studies have shown that PM-Que has a long-lasting circulation effect and the ability to target AS sites. Therefore, the PM-Que group has the best therapeutic effect and slows down the development of AS plaques to a certain extent. Compared with the other two drug-administered groups, the PM-Que group significantly inhibited the development of AS plaques. Combined with previous experiments, it shows that PM-Que has the advantages of a longer circulation effect and targeting AS plaque sites in the body, so it has a higher bioavailability and is effective against ApoE - / - The mice showed significant therapeutic effects.
[0121] Oil red O staining of the aorta is the overall situation of the plaque, which can only draw a conclusion about the proportion of the plaque area to the total area of the blood vessel, and cannot show the development of the plaque inside. Therefore, this example uses frozen sections of the root of the mouse aortic arch to further analyze the lipid deposition and collagen content inside the plaque. Fig.23 As shown, the plaques in the Control group contained a large amount of lipid deposition, indicating that severe AS lesions had occurred. Compared with the Control group, the lipids in the plaques of the Que and Mod-Que groups were relatively reduced. Compared with the Control group, the lipids in the plaques of the PM-Que group were significantly reduced, which slowed down the development of AS.
[0122] 4. PM-Que for ApoE - / - Evaluation of plaque stability in mice
[0123] Unstable AS plaque rupture leads to intravascular thrombosis, which can cause many vascular complications and bring great pain to patients. The necrotic core inside the AS plaque is an important indicator for evaluating whether the plaque is stable. In this study, the aortic arch root sections of mice were stained with toluidine blue, and the dark blue substance was the necrotic core. Fig.24 As shown, a large number of dark blue necrotic cores were distributed in the untreated Control group. The necrotic cores of the plaques in the Que, Mod-Que and PM-Que groups were all reduced compared with the Control group, with the PM-Que group having the least, indicating that PM-Que stabilized the plaques and reduced the risk of thrombosis in mice.
[0124] The extracellular matrix is mainly composed of collagen, non-collagen, elastin, proteoglycans and aminoglycans, and is one of the important components of the blood vessel wall. Matrix metalloproteinase 9 (MMP-9) is a member of the matrix metalloproteinase family. During the development of AS, MMP-9 degrades the extracellular matrix of AS plaques, leading to the rupture of AS plaques. Ruptured plaques are prone to aggregate in blood vessels, increasing the risk of thrombosis in patients. In this example, immunohistochemistry of MMP-9 was performed on slices of the root of the mouse aortic arch. The results are shown in Figure 2. Fig.25 As shown in the figure, there is a large amount of MMP-9 inside the plaques of the Control group, indicating that the plaques are extremely unstable and easy to rupture, and the mice are more likely to suffer from thrombosis. The MMP-9 content in the Que and Mod-Que groups decreased, which had a certain therapeutic effect on the plaques, increased the stability of the plaques, and reduced the risk of thrombosis. Compared with the other three groups, the PM-Que group had the lowest MMP-9 content, indicating that the PM-Que group had the best plaque stability and the mice had the lowest risk of thrombosis.
[0125] Both necrotic core and MMP-9 can be used as markers to assess whether the plaque is stable. After PM-Que treatment, the necrotic core and MMP-9 content in the mouse plaques were significantly reduced, indicating that PM-Que stabilized the plaque and reduced the risk of plaque fragmentation.
[0126] 5. PM-Que for ApoE - / - Effects of post-apoptosis on blood vessels in plaques in mice
[0127] Endothelial cells are a single layer of flat cells lining the inner surface of blood vessels. They have the function of angiogenesis and maintaining vascular integrity. Endothelial damage is an important factor in the development of AS, so the integrity of the endothelium is very important for the protection of AS. This example detected the expression of endothelial cell markers (CD31) in slices of the root of the mouse aortic arch. The results are as follows: Fig.26 As shown, the expression of CD31 in the Control group was not obvious, the expression of CD31 in the Que and Mod-Que groups increased, and the expression of CD31 in the PM-Que group was the most significant, indicating that PM-Que effectively maintained the integrity of the vascular endothelium and had a certain protective effect on the blood vessels.
[0128] Abnormal proliferation of macrophages in plaques is an important factor in promoting the development of AS. Therefore, understanding the number of macrophages in plaques can assess the degree of AS development. In this study, immunohistochemical analysis of macrophage markers (CD68) was performed on sections of the root of the mouse aortic arch. Fig. 27As shown in the figure, there was a large amount of CD68 expression in the plaques of the Control group. The CD68 expression in the Que, Mod-Que and PM-Que groups was lower than that in the Control group. After PM-Que treatment, the expression of CD68 in the plaques decreased most significantly, indicating that PM-Que effectively inhibited the abnormal proliferation of macrophages in the plaques.
[0129] Vascular smooth muscle cells (SMCs) are an important component of the human blood vessel wall, which can maintain blood pressure and regulate blood flow. However, the proliferation of smooth muscle cells and the increase of collagen fibers will form chondroitin-like lipid-containing necrotic lesions and vascular wall sclerosis. During the development of AS, SMCs will undergo "transformations" such as dedifferentiation, proliferation, and migration under certain stress conditions and promote the "fibrous cap" and necrotic core. Abnormal proliferation of SMCs will lead to. In this example, the root sections of the mouse aortic arch were subjected to immunohistochemical analysis of the SMCs marker (α-SMA). The results are as follows. Fig.28 As shown in the figure, the plaques in the Control group expressed a large amount of α-SMA. The α-SMA expression in the Que, Mod-Que and PM-Que groups was lower than that in the Control group, and the number of smooth muscle cells in the plaques decreased. After PM-Que treatment, the expression of α-SMA in the plaques was the lowest, and the number of smooth muscle cells decreased most significantly, which effectively inhibited the further development of AS.
[0130] The above results show that after PM-Que treatment, the number of endothelial cells in the plaques of mice increased, and the number of macrophages and smooth muscle cells decreased significantly, which inhibited the abnormal proliferation of macrophages and smooth muscle cells in the plaques, maintained the integrity of the blood vessels, and played an inhibitory role in the development of AS.
[0131] 6. Biosafety evaluation of PM-Que in mice after treatment
[0132] In order to determine whether the various organs of the mice had pathological lesions after treatment, the heart, liver, spleen, lung, and kidney of each group of mice were stained with HE. Fig.29 Compared with the Control group, no obvious organic lesions were found in the main organs of the mice in the Que, Mod-Que and PM-Que groups. The myocardial cells were arranged neatly and densely, the liver cells were arranged neatly and had normal morphology, the spleen tissue had clear boundaries, the alveoli of the lungs were arranged evenly, and the glomeruli had no obvious hyperplasia. No pathological lesions were found in various tissues, indicating that PM-Que has good biosafety.
[0133] The animal weight during treatment is an indicator of whether the nanomedicine has toxic side effects on animals. This study recorded and analyzed the weight of mice in each group during treatment. Fig.30As shown, the body weight of mice in each group did not change significantly during the one-month treatment, and the body weight was relatively balanced. There was a slight increase in body weight during the treatment, indicating that the appetite of mice during the treatment was not affected by the drug, proving that PM-Que had no obvious toxic side effects on mice.
[0134] After the treatment, blood was taken from each group of mice for routine blood tests and blood biochemistry tests. As shown in Table 2, except for cholesterol and LDL, the indicators between the groups were not much different and were all within the normal range. Increased CHO and LDL may be related to atherosclerosis and high-fat diet. The above results show that the PM-Que prepared in this study has good biosafety, excellent biocompatibility, no obvious toxic side effects on organisms, and is conducive to long-term treatment.
[0135] Table 2 Results of blood routine and blood biochemical tests of mice in each group
[0136]
[0137] The above-mentioned embodiments only express the specific implementation methods of the present application, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the protection scope of the present application. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the technical solution concept of the present application, and these all belong to the protection scope of the present application.
Claims
1. A phospholipid membrane quercetin nanoparticle, It is characterized in that It comprises a quercetin modified inner core and a phospholipid membrane on the outer layer of the inner core, wherein the molecular formula of the quercetin modified inner core is as shown in Formula 1:
2. The phospholipid membrane quercetin nanoparticles according to claim 1, It is characterized in that The particle size of the phospholipid membrane quercetin nanoparticles is 134.3±6.72nm, the polydispersity index PDI is 0.217, and the zeta potential is -14.4±0.97mV.
3. The method for preparing phospholipid membrane quercetin nanoparticles according to claim 1 or 2, It is characterized in that The steps include: (1) Using DMSO as solvent, the quercetin modified core material was fully dissolved to obtain Mod-Que solution for later use, and using ethanol as solvent, DSPE-PEG solution, DOPC solution, and cholesterol solution were prepared for later use; (2) adding ethanol aqueous solution to a reaction vessel and preheating to 35-40° C., and then rapidly adding DSPE-PEG solution, DOPC solution, cholesterol solution, Mod-Que solution and distilled water under stirring; (3) Introducing compressed air into the reaction system, and removing the compressed air after the reaction is completed, thereby obtaining a phospholipid membrane quercetin nanoparticle solution.
4. The method for preparing phospholipid membrane quercetin nanoparticles according to claim 3, It is characterized in that The concentrations of the solutions prepared in step (1) are: the concentration of the Mod-Que solution is 20 mg / mL, and the concentrations of the DSPE-PEG solution, the DOP C solution, and the cholesterol solution are all 5 mg / mL.
5. The method for preparing phospholipid membrane quercetin nanoparticles according to claim 4, It is characterized in that In step (2), the volume ratio of DSPE-PEG solution, DOPC solution, cholesterol solution, Mod-Que solution and distilled water is 1:20:5.2:2.4:
80.
6. The method for preparing phospholipid membrane quercetin nanoparticles according to claim 4, It is characterized in that The volume ratio of the ethanol aqueous solution to distilled water is 1:1, and the ethanol aqueous solution is an ethanol aqueous solution in which ethanol accounts for 30% by volume.
7. Use of the phospholipid membrane quercetin nanoparticles according to claim 1 or 2 in the preparation of drugs for interventional treatment of atherosclerosis.
